Bayer agrees to help CureVac produce coronavirus vaccine

German drug conglomerate Bayer will help CureVac manufacture tens of millions more doses of the biotech's experimental coronavirus vaccine beginning as soon as the end of this year, company executives said in a Monday briefing with the German health minister. Bayer and CureVac are already co-developing the vaccine, with the large pharma providing support for clinical testing and regulatory discussions in other countries. Now, after discussions with the German government, Bayer has also agreed to make 160 million doses of CureVac's shot in 2022 CureVac recently began a Phase 2/3 study testing whether its vaccine prevents COVID-19. The company aims to enroll into the trial some 36,000 volunteers in Europe and South America. Early results could be available by the end of March, CureVac's CFO Pierre Kemula recently told BioPharma Dive.